This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724253 | PMC |
| http://dx.doi.org/10.1002/cpt.280 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Consensus findings of an International Workshops on Genotoxicity Testing workshop on using transcriptomic biomarkers to predict genotoxicity.
Environ Mol Mutagen
January 2025
Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
Article Synopsis
- Gene expression biomarkers can help identify both genotoxic and non-genotoxic carcinogens, which could reduce the need for animal testing.
- In August 2022, a workshop reviewed current methods for using transcriptomic profiling to detect genotoxic chemicals, examining 1341 papers to find reliable biomarkers.
- The analysis identified two promising in vivo biomarkers and three in vitro biomarkers that show over 92% predictive accuracy and can be adapted for various testing conditions, with support from workshop participants for their regulatory adoption.
Management of adverse effects following additively manufactured subperiosteal jaw implantation in the maxilla.
J Stomatol Oral Maxillofac Surg
December 2024
Face Ahead® Surgicenter, Belgium and Ziekenhuis aan de Stroom, Campus GZA, B-2018, Antwerp, Belgium. Electronic address:
Objective: This expert opinion presents provisional guidelines for addressing complications associated with Additively Manufactured Subperiosteal Jaw Implants (AMSJI®) in patients with severe maxillary atrophy. AMSJI®'s custom design, supported by finite element analysis (FEA), allows precise placement that avoids critical anatomical structures and minimizes complications relative to alternative solutions.
Materials And Methods: Data were gathered through firsthand experiences, direct communications, and insights from international workgroup meetings.
Mitigation of AI adoption bias through an improved autonomous AI system for diabetic retinal disease.
NPJ Digit Med
December 2024
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA.
Where adopted, Autonomous artificial Intelligence (AI) for Diabetic Retinal Disease (DRD) resolves longstanding racial, ethnic, and socioeconomic disparities, but AI adoption bias persists. This preregistered trial determined sensitivity and specificity of a previously FDA authorized AI, improved to compensate for lower contrast and smaller imaged area of a widely adopted, lower cost, handheld fundus camera (RetinaVue700, Baxter Healthcare, Deerfield, IL) to identify DRD in participants with diabetes without known DRD, in primary care. In 626 participants (1252 eyes) 50.
View Article and Find Full Text PDFGuidelines for the standardized diagnosis and treatment of non-specific orbital inflammation (2024).
Int J Ophthalmol
December 2024
Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China.
Non-specific orbital inflammation (NSOI) is a non-infectious orbital inflammation. Although it is often considered the most common diagnosis in orbital biopsies, it is an exclusionary diagnosis that requires ruling out systemic disease or other possible causes. Its characteristics include acute orbital signs and symptoms, including pain, proptosis, periorbital edema, chemosis, diplopia, and visual impairment.
View Article and Find Full Text PDFOutcome of IWGT workshop on transcriptomic biomarkers for genotoxicity: Key considerations for bioinformatics.
Environ Mol Mutagen
December 2024
Department of Biology, Faculty of Science, University of Ottawa, Ottawa, Ontario, Canada.
As a part of the International Workshop on Genotoxicity Testing (IWGT) in 2022, a workgroup was formed to evaluate the level of validation and regulatory acceptance of transcriptomic biomarkers that identify genotoxic substances. Several such biomarkers have been developed using various molecular techniques and computational approaches. Within the IWGT workgroup on transcriptomic biomarkers, bioinformatics was a central topic of discussion, focusing on the current approaches used to process the underlying molecular data to distill a reliable predictive signal; that is, a gene set that is indicative of genotoxicity and can then be used in later studies to predict potential DNA damaging properties for uncharacterized chemicals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!